Clinical Trials Directory

Trials / Completed

CompletedNCT01527734

Comparison Study of Liquid and Lyophilized Formulations of Subcutaneous Tetrodotoxin (TTX) in Healthy Volunteers

COMPARISON OF THE PHARMACOKINETICS AND SAFETY OF LIQUID (30 µg) AND LYOPHILIZED TETRODOTOXIN (15 µg AND 30 µg) FOLLOWING SINGLE AND TWICE DAILY SUBCUTANEOUS DOSE ADMINISTRATION TO HEALTHY VOLUNTEERS-DETERMINATIONS IN BLOOD AND URINE

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
44 (actual)
Sponsor
Wex Pharmaceuticals Inc. · Industry
Sex
All
Age
18 Years – 55 Years
Healthy volunteers
Accepted

Summary

The study design is a randomized, double-blind, placebo-controlled, parallel-group, dose comparison with a open-label, crossover, formulation comparison.

Conditions

Interventions

TypeNameDescription
DRUGTetrodotoxin15ug and 30ug once or twice a day for 1 or 2 days.
DRUGplacebo1ml once or twice a day for 1 or 2 days.

Timeline

Start date
2011-12-01
Primary completion
2012-01-01
First posted
2012-02-07
Last updated
2012-02-08

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01527734. Inclusion in this directory is not an endorsement.

Comparison Study of Liquid and Lyophilized Formulations of Subcutaneous Tetrodotoxin (TTX) in Healthy Volunteers (NCT01527734) · Clinical Trials Directory